SEC Comment Letter for Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083) (SNOA) — Feb 9, 2009

Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083)
Date: Feb. 9, 2009 · CIK: 0001367083 · Accession: 0000000000-09-006606

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

February 5, 2009

Author

Angela J. Crane

Form

UPLOAD

Company

Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083)

Letter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE Mail Stop 3030 February 5, 2009 Mr. Robert Miller Chief Financial Officer Oculus Innovative Sciences, Inc. 1129 N. McDowell Blvd. Petaluma, CA 94954 RE: Oculus Innovative Sciences, Inc. Form 10-K for the fiscal year ended March 31, 2008 Filed May June 13, 2008 File No. 1-33216

Dear Mr. Miller: We have completed our review of your Form 10-K and related filings and do not, at this time, have any further comments. S i n c e r e l y , A n g e l a J . C r a n e A c c o u n t i n g B r a n c h C h i e f

Show Raw Text

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

       DIVISION OF
CORPORATION FINANCE

 Mail Stop 3030
February 5, 2009

  Mr. Robert Miller Chief Financial Officer Oculus Innovative Sciences, Inc. 1129 N. McDowell Blvd. Petaluma, CA 94954   RE: Oculus Innovative Sciences, Inc.
  Form 10-K for the fiscal  year ended March 31, 2008
  Filed May June 13, 2008
  File No. 1-33216

Dear Mr. Miller:   We have completed our review of your Form 10-K and related filings and do not,
at this time, have any further comments.              S i n c e r e l y ,           A n g e l a  J .  C r a n e         A c c o u n t i n g  B r a n c h  C h i e f

SecProbe.io